Is FOXO4-DRI Safe? Safety Profile 2026 — PeptidePrices

Q: Is FOXO4-DRI safe?

FOXO4-DRI has a safety rating of 3/10 in our methodology — caution. Experimental senolytic that works by disrupting the FOXO4–p53 interaction. p53 is the master tumor-suppressor protein — modulating it carries serious theoretical oncogenic risk, and there is zero human safety data. Animal data only.

Q: Is FOXO4-DRI FDA approved?

FDA status: Not FDA-approved. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified FOXO4-DRI?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest FOXO4-DRI listings for prices ranked by COA tier and $/mg.

Safety Profile

FOXO4-DRI

Updated today

Senolytic Peptide

3/10Caution

How we score compound safety →

Primary use: Senolytic / longevity research

Regulatory Status

Not FDA-approved

Safety Summary

Experimental senolytic that works by disrupting the FOXO4–p53 interaction. p53 is the master tumor-suppressor protein — modulating it carries serious theoretical oncogenic risk, and there is zero human safety data. Animal data only.

FOXO4-DRI's 3/10 rating is in our caution tier. Either documented side-effect patterns are concerning, the human safety dataset is too thin to make confident statements, or the compound is under active regulatory scrutiny. We recommend reviewing the full notes above and consulting a licensed physician before any research use. Researchers often consider Epithalon (Epitalon) and NAD+ as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeD-retro-inverso FOXO4–p53 interaction peptide

Molecular WeightNot well characterized publicly

Amino AcidsD-amino-acid peptide (length not standardized)

CAS NumberNot standardized

Storage

Lyophilized−20°C, long-term stable

Reconstituted2–8°C, within 30 days

Protect from light
Avoid repeated freeze-thaw
Limited public characterization

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with FOXO4-DRI

Full FOXO4-DRI profile Cheapest FOXO4-DRI deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.